RxDoctor Payments Data

Claudius Dawson, MD

Family Medicine · Summerville, SCNPI 1780675306

Payments from drug & device makers

$5,938in general payments, 2019–2025

Across 313 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$793
  • Novo Nordisk$775
  • Novartis$443
  • GSK$347
  • Lilly USA, LLC$334
  • Sanofi-aventis U.S. LLC$317
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$5,938100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,938 in reported general payments places this provider in the 85th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$449,359
Medicare patients
600
Services billed
13,113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide229$248,565
FarxigaDapagliflozin Propanediol156$118,730
EliquisApixaban109$104,906
Trelegy ElliptaFluticasone/Umeclidin/Vilanter79$84,691
JardianceEmpagliflozin55$73,128
TrulicityDulaglutide43$58,540
JanuviaSitagliptin Phosphate53$57,754
MounjaroTirzepatide31$52,322
RybelsusSemaglutide18$31,042
Bydureon BciseExenatide Microspheres13$24,735
LinzessLinaclotide27$23,034
JanumetSitagliptin Phos/Metformin Hcl27$19,191
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog31$19,104
MyrbetriqMirabegron17$17,166
Tresiba Flextouch U-100Insulin Degludec16$11,366

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$775$279,607247 claims
AstraZenecaFarxiga, Symbicort$222$126,137176 claims
Lilly USA, LLCTrulicity, Mounjaro$334$110,86274 claims
PfizerEliquis, Paxlovid$203$107,731128 claims
GSKTrelegy Ellipta, Breo Ellipta$347$90,27692 claims
AbbVieLinzess$793$23,03427 claims
Astellas Pharma US IncMyrbetriq$168$17,16617 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$317$11,27113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Summerville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →